Shandong Sinobioway Biomedicine Co., Ltd. (SHE:002581)

Market Cap	5.44B
Revenue (ttm)	360.41M
Net Income (ttm)	-137.31M
Shares Out	659.74M
EPS (ttm)	-0.21
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	15,703,600
Average Volume	7,019,057
Open	8.54
Previous Close	8.24
Day's Range	7.42 - 8.54
52-Week Range	7.42 - 14.43
Beta	0.48
RSI	30.77
Earnings Date	Apr 24, 2025

About SHE:002581

Shandong Sinobioway Biomedicine Co., Ltd. engages in the research and development, production, and sale of pharmaceutical intermediates in China. The company manufactures and supplies trimethyl orthoformate, triethyl orthoformate, trimethyl orthoacetate, phosphorous acid, ethyl formate, and trimethyl acetate and its by-products. It also offers Anfulan, a human interferon α2b injection; Jiefu, a human interferon α2b spray; Enjingfu, a mouse nerve growth factor for injection; and Bellaph, a combined hepatitis A and B vaccine. In addition, the com...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2000
• Employees: 507
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 002581

Financial Performance

In 2024, SHE:002581's revenue was 360.41 million, a decrease of -16.14% compared to the previous year's 429.79 million. Losses were -137.31 million, -58.70% less than in 2023.